ICYMI: Chuck Hess, vice president and general manager of the U.S. Surgical Divison at Bausch + Lomb, shares what's in the company's surgical pipeline at the 2019 annual American Society of Retina Specialists meeting in Chicago.
In the first part of his Clinical Innovation series, Josh Mali, MD, shares how this novel home-use device is the new standard of care for AMD monitoring. Future blogs in the series will discuss the increased efficacy of patient monitoring and present case examples.
The 2017 meeting of the American Academy of Ophthalmology will convene in New Orleans from Nov. 11 to 14. Go to www.aao.org/annual meeting for the latest updates
How do the newer anticoagulant medications compare with warfarin when it comes to the risk of intraocular bleeding? A meta-analysis published in JAMA Ophthalmology did a systematic review of phase 3 randomized trials looking at over 100,000 patients.
When dealing with patients with retinal disease, macular disease, or a meaningful risk of retinal detachment, certain types of IOLs should be avoided due to potential complications.
Is there risk between intravitreal injections and posterior capsule rupture during cataract surgery?
Intravitreal injections and posterior capsule rupture during cataract surgery: is there a risk? Research published in the American Journal of Ophthalmology may have an answer.
Cataract surgery in patients with coexisting uveitis is more challenging than managing either condition alone. Surgeons must answer a different set of questions and consider alternative management strategies, said Debra A. Goldstein, MD, FRSC, professor of ophthalmology and director of the Uveitis Service, Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago.
Retinal issues can impact cataract surgery outcomes, especially for those with multifocal or other premium lenses. While multifocal lenses may allow the patient to see more clearly across a range of distances, they may also decrease the amount of light that reaches the retina, exacerbating any issues that may already be present.
A 6-month analysis from the REINFORCE study of the dexamethasone intravitreal implant Ozurdex found an average of one- to two-line vision gains and no new safety concerns.